Neurocrine Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Neurocrine Biosciences has a total shareholder equity of $2.4B and total debt of $122.8M, which brings its debt-to-equity ratio to 5.1%. Its total assets and total liabilities are $3.5B and $1.1B respectively. Neurocrine Biosciences's EBIT is $470.4M making its interest coverage ratio -7.1. It has cash and short-term investments of $1.2B.
Key information
5.1%
Debt to equity ratio
US$122.80m
Debt
Interest coverage ratio | -7.1x |
Cash | US$1.21b |
Equity | US$2.39b |
Total liabilities | US$1.09b |
Total assets | US$3.47b |
Recent financial health updates
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Recent updates
Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet
Mar 08Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Dec 08Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.8B) exceed its short term liabilities ($712.9M).
Long Term Liabilities: NBIX's short term assets ($1.8B) exceed its long term liabilities ($373.4M).
Debt to Equity History and Analysis
Debt Level: NBIX has more cash than its total debt.
Reducing Debt: NBIX's debt to equity ratio has reduced from 96.1% to 5.1% over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (525.6%).
Interest Coverage: NBIX earns more interest than it pays, so coverage of interest payments is not a concern.